Makhmudova Umidakhon, Schulze P Christian, Davis Harry R, Weingärtner Oliver
Klinik für Innere Medizin I, Universitätsklinikum Jena, Jena 07747, Germany.
Synergy Partners RD Solutions, Synergy Partners RD Solutions, Gaithersburg, MD 20850, United States.
World J Cardiol. 2021 Oct 26;13(10):526-532. doi: 10.4330/wjc.v13.i10.526.
More than twenty years ago, knowledge about the importance of cholesterol absorption and the potential therapeutic effect of its inhibition led to the discovery and clinical application of the first and only cholesterol absorption inhibitor to date - ezetimibe. Since then, ezetimibe has become a well-recognized player in lipid-lowering therapy. Recent findings of IMPROVE-IT and EWTOPIA 75 imply that elderly patients over the age of 75 years in particular benefit from ezetimibe. This review summarizes the evidence, discusses the possible underlying pathophysiological mechanisms and calls for a change in future dyslipidemia guidelines.
二十多年前，关于胆固醇吸收的重要性及其抑制作用的潜在治疗效果的知识，促成了首个也是迄今为止唯一一种胆固醇吸收抑制剂——依折麦布的发现及临床应用。自那时起，依折麦布已成为降脂治疗中广为人知的药物。IMPROVE-IT和EWTOPIA 75的最新研究结果表明，尤其是75岁以上的老年患者能从依折麦布中特别获益。本综述总结了相关证据，讨论了可能的潜在病理生理机制，并呼吁对未来的血脂异常指南做出改变。
